GF+(Growth Factor Plus) 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별 및 부문별 예측(2026-2033년)

Growth Factor Plus Market Summary

The global growth factor plus market size was valued at USD 125.7 million in 2025 and is projected to reach USD 201.3 million by 2033, growing at a CAGR of 6.2% from 2026 to 2033. The market encompassing advanced skincare formulations enriched with biologically active growth factors is gaining strong momentum as consumers increasingly shift toward science-backed, regenerative beauty solutions.

Growth factors, naturally occurring proteins that regulate cell growth, proliferation, and repair, have been widely studied for their roles in wound healing and tissue regeneration. Clinical research has demonstrated that growth factors such as epidermal growth factor (EGF) can significantly enhance skin repair and stimulate collagen production, making them highly relevant for anti-aging and dermatological applications. This scientific foundation has helped position GF+ products as a premium segment within the broader cosmeceuticals market.

One of the primary drivers of market growth is the rising consumer demand for clinically validated skincare products. Modern consumers are increasingly informed and are seeking formulations supported by dermatological research rather than traditional cosmetic claims. Studies have shown that topical application of growth factors can improve skin texture, reduce wrinkles, and accelerate healing processes, reinforcing their credibility. In addition, advancements in biotechnology have enabled the development of bioengineered and recombinant growth factors, improving product stability and efficacy and further fueling adoption across both medical and aesthetic skincare segments.

Advantages/Importance of Growth Factor Plus (GF+):

Stimulates cellular regeneration and repair

Enhances collagen and elastin production

Accelerates wound healing and reduces inflammation

Improves skin texture, tone, and pigmentation

Supports hair follicle stimulation and scalp health

Reduces recovery time after aesthetic procedures

The expanding use of GF+ products in post-procedure recovery and minimally invasive aesthetic treatments further fuels the market growth. Dermatology clinics and aesthetic practitioners are increasingly recommending growth factor-based serums and creams following procedures such as laser resurfacing, microneedling, and chemical peels. These products help accelerate healing, reduce inflammation, and enhance overall treatment outcomes. The integration of GF+ formulations into professional skincare protocols highlights their growing clinical acceptance and underscores their importance in bridging the gap between cosmetics and therapeutic dermatology.

The premium skincare trend and increasing consumer willingness to invest in high-performance products are also significantly contributing to market expansion. Growth factor serums, often positioned as luxury or medical-grade skincare, are gaining popularity through dermatology clinics, medspas, and high-end retail channels. For instance, curated product offerings featuring growth factors are being prominently highlighted by skincare platforms and clinics, showcasing their effectiveness in anti-aging and skin rejuvenation routines. This premium positioning not only drives higher margins but also enhances brand differentiation in a crowded skincare market.

Furthermore, media influence and beauty industry endorsements are playing a crucial role in accelerating consumer adoption. Leading fashion and beauty publications have increasingly featured growth factor serums as cutting-edge skincare solutions, often highlighting their benefits in reducing fine lines and improving skin elasticity. This visibility, combined with endorsements from dermatologists and skincare experts, is helping to normalize the use of GF+ products among a broader consumer base and boosting demand across both developed and emerging markets. Ongoing research into stem cell-derived growth factors and plant-based alternatives is further diversifying the product landscape, making GF+ solutions more accessible and appealing to a wider audience. As scientific validation continues to strengthen and product innovation accelerates, the global GF+ market is expected to witness sustained growth driven by its unique combination of clinical efficacy and cosmetic appeal.

Global Growth Factor Plus Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global growth factor plus market report based on product, application, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Serums
• Creams & Gels
• Injectables
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Anti-Aging & Skin Rejuvenation
• Scar Treatment & Wound healing
• Hair Growth / Scalp Treatment
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Offline
• Online
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Distribution Channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Growth Factor Plus Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Growth Factor Plus Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Growth Factor Plus Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Growth Factor Plus Market: Product Movement Analysis
• 4.3. Growth Factor Plus Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Serums
  • 4.5.1. Serums Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Creams & Gels
  • 4.6.1. Creams & Gels Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Injectables
  • 4.7.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Growth Factor Plus Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Growth Factor Plus Market: Application Movement Analysis
• 5.3. Growth Factor Plus Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Anti-Aging & Skin Rejuvenation
  • 5.5.1. Anti-Aging & Skin Rejuvenation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Scar Treatment & Wound healing
  • 5.6.1. Scar Treatment & Wound healing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Hair Growth / Scalp Treatment
  • 5.7.1. Hair Growth / Scalp Treatment Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Growth Factor Plus Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Growth Factor Plus Market: Distribution Channel Movement Analysis
• 6.3. Growth Factor Plus Market by Distribution Channel Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Offline
  • 6.5.1. Offline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Online
  • 6.6.1. Online Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Growth Factor Plus Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Growth Factor Plus Market Movement Analysis
• 7.3. Growth Factor Plus Market: Regional Estimates & Trend Analysis by Product & Source
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. U.S. Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Canada Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Scenario
    • 7.5.4.5. Mexico Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Scenario
    • 7.5.7.5. UK Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Scenario
    • 7.5.8.5. Germany Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Scenario
    • 7.5.9.5. France Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement Scenario
    • 7.5.10.5. Italy Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement Scenario
    • 7.5.11.5. Spain Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement Scenario
    • 7.5.12.5. Denmark Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement Scenario
    • 7.5.13.5. Sweden Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement Scenario
    • 7.5.14.5. Norway Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Japan Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. China Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. India Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. South Korea Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Scenario
    • 7.6.6.5. Australia Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Scenario
    • 7.6.7.5. Thailand Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Scenario
    • 7.7.2.5. Brazil Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Scenario
    • 7.7.3.5. Argentina Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Scenario
    • 7.8.2.5. South Africa Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Scenario
    • 7.8.3.5. Saudi Arabia Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Scenario
    • 7.8.4.5. UAE Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Scenario
    • 7.8.5.5. Kuwait Growth Factor Plus Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. SkinMedica
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. BIOEFFECT
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Neocutis
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Bharat Biotech
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Smith & Nephew
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. ZO Skin Health
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. CALECIM Professional
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Galderma (Alastin Skincare)
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. The Ordinary
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Perricone MD
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives